Latest Complement component 3 Stories
Pursuing a relatively untapped route for regulating the immune system, an international team of researchers has designed and conducted initial tests on molecules that have the potential to treat diseases involving inflammation, such as asthma, rheumatoid arthritis, stroke and sepsis.
This week, the highly-respected US Academy of Sciences journal (PNAS) published an article describing how the first line of defence of the human immune system distinguishes between microbes and the body's own structures.
How molecules of the oldest branch of the human immune system have interconnected has remained a mystery.
SAN FRANCISCO, July 28 /PRNewswire/ -- InCode BioPharmaceutics, Inc. today announced favorable results of its preclinical primate toxicity study demonstrating no adverse events and reduction of key markers of potency for its lead drug candidate, rC3-1.
SAN FRANCISCO, July 23 /PRNewswire/ -- InCode BioPharmaceutics, Inc., an emerging biopharmaceutical company, today announced preclinical test results demonstrating the utility of their lead drug candidate rC3-1 for the treatment of the rare chronic blood disorder paroxysmal nocturnal hemoglobinuria (PNH).
- The governor of a province or people.